Need WBC count advise. - American Cancer Society

My husband ended his 5FU 6 months ago. He had issues with a drop in his WBC counts. He took Neupogen for the last two months of treatments. The Neupogen substantially raised his counts over 15. Had one of his first blood tests today and his WBC count was ...

Royalty Pharma Raises $600 Million of Debt - PR Inside

Leading products in Royalty Pharma's portfolio include: Abbott's Humira®, Johnson and Johnson's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan ...

8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy - Seekingalpha.com

Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body ...

South Africa: Cancer Services Take Strain in Gauteng - AllAfrica.com

bioscrub and savlon (all disinfectants); and neupogen (generates specific white blood cells in patients on chemo with low white cell counts). Chemotherapy patients were also turned away last week after being told their drugs were out of stock at the time.

RNCOS Releases a New Report - G-CSF Biosimilars Market Forecast to 2015 - SBWire

In 2010, the G-CSF biosimilars had a 33% share in the global biosimilars market. It is expected that the patent expiries of Neupogen (filgrastim) in 2013 and Neulasta (pegfilgrastim) in 2015 will make the way for the entry of G-CSF biosimilars ...

Antares Reports A Modest Reassuring Advancement - Seekingalpha.com

Antares (AIS) almost broke even in Q1 2012 as the company reported: Net loss was approximately $0.1 million and $1.4 million for the first quarters of 2012 and 2011, respectively, and net loss per share was $0.00 and $0.02 in the first quarters of 2012 and ...

Slow, costly process stymies generic biotech drugs - msnbc.com

U.S. patent expirations for biotech drugs will occur in 2013 for Epogen and another Amgen drug, white blood cell booster Neupogen. The FDA said in early February it had held discussions for a total of 35 potential biosimilar products ...